The highest rates of <i>HER2</i> amplification were observed in patients with tumors of the esophagus/stomach (12.9%), followed by tumors of the bladder/urinary tract (10.6%), breast (9.5%), biliary tract (8.4%), and uterus (8.4%). This evidence concerns the gene ERBB2 and urinary bladder neoplasm.